UNOFFICIAL STOCK DOSSIER / Q2 2026

DICKPILL$HIMS

$HIMS is the stock ticker for Hims & Hers. The “dick pill” nickname comes from the brand's famous erectile-dysfunction business—not from a pill that makes penises bigger.

OPEN THE CASE FILE ↓CHECK THE SOURCES ↗

PARODY + EXPLAINER · NOT AFFILIATED WITH HIMS & HERS · NOT MEDICAL OR FINANCIAL ADVICE

QUERY EVIDENCEMORE WRAPPERS. LESS FANTASY.

SEARCH:
“DICK PILL
HIMS STOCK
CONDOM”

THE 15-SECOND EXPLANATION

WHAT DOES “DICK PILL”
HAVE TO DO WITH $HIMS?

There is no security called “Dick Pill.” $HIMS is the NYSE ticker for Hims & Hers Health, Inc., a telehealth company. Men's sexual health helped make its brand recognizable, so traders gave the whole stock a crude, memorable nickname.

01THE COMPANY

HIMS & HERS

A consumer-health platform spanning sexual health, hair, weight, dermatology, mental health and more.

02THE FAMOUS CATEGORY

ED TREATMENT

Hims made online access to clinician-evaluated sildenafil and tadalafil central to its early cultural identity.

03THE INTERNET NICKNAME

“DICK PILL STOCK”

Traders compressed one recognizable category into shorthand for the entire public company and its shares.

REALITY CHECK

Prescription ED medicines treat erectile dysfunction; they are not penis-enlargement products. And $HIMS represents a diversified healthcare business—not a single pill, condom or meme.

THE THESIS IN ONE LINE

REVENUE IS GROWING. SUBSCRIBERS ARE GROWING. SO ARE THE RISKS, COSTS AND EXPECTATIONS.

MEME DECODER / CLICK A FILE

FOUR LAYERS.
ONE BAD NICKNAME.

01 / INTERNET SHORTHAND

“Dick pill stock” is the joke, not the business model.

Online traders compress a broad consumer-health company into its loudest, easiest-to-meme association: erectile-dysfunction treatment. It is memorable, vulgar and radically incomplete.

Translation: one provocative product category became a nickname for an entire listed company.

BRAND DECODE / NOT AN OFFICIAL AD

SELL THE
UNSAYABLE.

hims&hersBRAND ANALYSIS / UNOFFICIAL

01 / TONE

PLAIN WORDS.

The brand makes awkward health topics feel ordinary: direct language, little ceremony and a checkout-like path into care.

02 / LOOK

SOFT SHELL.

Cream, blush and restrained packaging lower the temperature. The site keeps that softness, then adds black-and-red market graphics so the analysis still has teeth.

03 / PRODUCT LANGUAGE

DISCREET, THEN MEMEABLE.

Hims and Hers are trademarks of their owners. This independent editorial uses the names and linked product imagery to discuss the public company; it does not reproduce the official logo or claim an endorsement.

Q2 REVENUE$753.2M

YEAR OVER YEAR+38%

SUBSCRIBERS2.891M

GROSS MARGIN64%

Quarter ended June 30, 2026 · company-reported, unaudited · not a live market quote

$HIMS / THE ACTUAL FILE

BULLS. BEARS.
BONERS.

Sexual health made the brand famous; weight loss and global expansion now move far more of the financial conversation. The Q2 numbers show fast top-line growth alongside weaker margins, losses and a live regulatory overhang.

01STIGMATIZED PROBLEM

Private health issue

ED and other sensitive conditions are awkward to discuss.

02DIRECT-TO-CONSUMER UX

Online intake

A provider reviews health information and decides on care.

03INTERNET COMPRESSION

“Dick pill stock”

A complex platform becomes one aggressively simple label.

ISSUER SNAPSHOT / Q2 2026

REVENUE: $753.2M · +38% year over year
SUBSCRIBERS: 2.891M · +19% year over year
REVENUE / SUB: $92 monthly · +21% year over year
GROSS MARGIN: 64% · down from 76% in Q2 2025
NET RESULT: $(86.3)M loss · versus $42.5M income
FY26 GUIDE: $3.1B–$3.3B revenue · $275M–$325M adj. EBITDA

READ THE Q2 2026 10-Q ↗

THE INVESTMENT CASE / BOTH SIDES

THE CHART NEEDS
A COUNTERARGUMENT.

BULL CASE / WHY IT COULD WORK

THE FRONT DOOR GETS BIGGER.

Q2 revenue grew 38% and subscribers grew 19%.
Monthly revenue per average subscriber rose 21% to $92.
International acquisitions expanded the platform across major markets and drove rapid rest-of-world growth.
Management raised 2026 revenue guidance to $3.1B–$3.3B.

THE TENSION / GROWTH COSTS MONEY

38%REVENUE GROWTH

VS.

−12 ptsGROSS-MARGIN CHANGE

Q2 2026 compared with Q2 2025.

BEAR CASE / WHAT CAN BREAK

THE FINE PRINT GETS REAL.

Gross margin fell to 64%; net income swung to a loss.
The 10-Q records a roughly $60M accrual tied to the FTC matter; the allegations remain contested and unresolved.
Regulatory pressure around mass-marketed compounded GLP-1 products coincided with a strategic shift in the U.S. weight-loss offering.
Acquisitions, fulfillment, privacy, clinical quality and paid acquisition all add execution risk.

OUR READ / SEPTEMBER 4, 2026

$HIMS is a high-growth, high-expectation health-platform bet. The operating momentum is real; so is the deterioration in Q2 profitability and the regulatory uncertainty. The decisive questions are whether subscriber economics hold, margins recover after the weight-loss reset and international expansion creates durable—not merely acquired—growth.

DO NOT MIX THESE DRAWERS

THREE THINGS
THE MEME MASHES TOGETHER.

CONDOM ≠ PRESCRIPTION ≠ SUPPLEMENT ≠ SHARE CERTIFICATE

THE “GROW IT” INTERNET SPIRAL

THREE MEMES.
ZERO MIRACLES.

The joke is the escalating desperation: tape measure, cursed DIY engineering, then the radical discovery that a licensed clinician is a better source than an anonymous forum.

DAY 1: NEW TAPE MEASURE

A fully clothed man solemnly measuring a cucumber at a bathroom counter

“THE CUCUMBER IS MY CONTROL GROUP.”

01 / THE OPTIMISM PHASE

THE INTERNET SAID IT WORKS

A fully clothed man admiring an absurd homemade contraption built from gym equipment and a balloon

THE INTERNET ALSO BUILT THIS.

02 / THE HARDWARE PHASE

87 TABS LATER

A tired fully clothed man holding a phone with a clinician on screen while ridiculous props cover the table

PLOT TWIST: ASK A CLINICIAN.

03 / THE REALITY PHASE

PROP COMEDY, NOT A HOW-TO: no gadget, supplement or “hack” shown is presented as effective. FDA warns that some products marketed for sexual enhancement contain hidden drug ingredients.

WHAT THE STOCK ACTUALLY CARES ABOUT

BEYOND THE
PUNCHLINE.

01 / SUBSCRIBER ECONOMICS

Q2 ended with 2.891M subscribers, up 19%, while monthly revenue per average subscriber reached $92, up 21%. The next question is what retention and acquisition spend are required to sustain it.

02 / MARGIN RECOVERY

Gross margin dropped 12 percentage points year over year to 64%, and adjusted EBITDA fell despite revenue growth. A bull thesis needs evidence that the reset and expansion costs normalize.

03 / REGULATORY + PRIVACY EXECUTION

Hims announced a strategic shift in its U.S. weight-loss offer amid FDA scrutiny of compounded GLP-1 marketing. Separately, the FTC and state partners allege deceptive billing, cancellation and privacy practices; Hims disputes the allegations. These are live business risks, not footnote decoration.

04 / ORGANIC VS. ACQUIRED GROWTH

Q2 rest-of-world revenue surged after acquisitions while U.S. revenue grew 16%. Investors should separate acquired scale from durable organic demand and watch integration execution.

05 / VALUATION + EXPECTATIONS

Even excellent companies can be poor investments at the wrong price. Compare market value with credible revenue, margin and cash-flow scenarios instead of treating a memorable ticker as a recommendation.

SEARCH RECEIPT / 20 FRAMES

THE QUERY
IS THE AESTHETIC.

A denser pass through “dick pill HIMS stock condom”: more sealed wrappers, less original illustration, and enough product imagery to show exactly how the meme assembled itself.

GOOGLE_IMAGE_RECEIPT.HTML20 RESULTS / LOOPING

CONDOM

Clockstopper box + wrappereBay result ↗CONDOM

Clockstopper multi-packeBay result ↗CONDOM

Clockstopper retail boxWalgreens result ↗CONDOM

Delay-condom packagingGoogle Images result ↗CONDOM

Retail condom listingDoorDash result ↗CONDOM

Single sealed wrapperHims result ↗PRESCRIPTION

ED product line-upHims result ↗PRESCRIPTION

Viagra packetHims result ↗PRESCRIPTION

Tadalafil packetHims result ↗PRESCRIPTION

Hard Mints packageHims result ↗PRESCRIPTION

Prescription bottleHims result ↗PRESCRIPTION

Bottle + tablet studyHims result ↗REVIEW

Tablet on fingertipInnerbody result ↗PILL

Blue Hims tabletHims result ↗PILL

Green Hims tabletHims result ↗PILL

Dark Hims tabletHims result ↗PILL

Round blue tabletHims result ↗PILL

Round yellow tabletHims result ↗PILL

Yellow tablet studyHims result ↗PILL

Pink tablet studyHims result ↗

PILL

Pink tablet studyHims result ↗PILL

Yellow tablet studyHims result ↗PILL

Round yellow tabletHims result ↗PILL

Round blue tabletHims result ↗PILL

Dark Hims tabletHims result ↗PILL

Green Hims tabletHims result ↗PILL

Blue Hims tabletHims result ↗REVIEW

Tablet on fingertipInnerbody result ↗PRESCRIPTION

Bottle + tablet studyHims result ↗PRESCRIPTION

Prescription bottleHims result ↗PRESCRIPTION

Hard Mints packageHims result ↗PRESCRIPTION

Tadalafil packetHims result ↗PRESCRIPTION

Viagra packetHims result ↗PRESCRIPTION

ED product line-upHims result ↗CONDOM

Single sealed wrapperHims result ↗CONDOM

Retail condom listingDoorDash result ↗CONDOM

Delay-condom packagingGoogle Images result ↗CONDOM

Clockstopper retail boxWalgreens result ↗CONDOM

Clockstopper multi-packeBay result ↗CONDOM

Clockstopper box + wrappereBay result ↗

Search-result thumbnails are reproduced for commentary and visual reference. Rights remain with their respective sources. Select a frame to visit the linked source or search result.

PRIMARY RECEIPTS

READ PAST THE MEME.

BOTTOM LINE / NO CAPSULE REQUIRED

KEEP THE MEME.
LOSE THE CONFUSION.

“Dick pill stock” is sticky shorthand. The bull case is growth, higher subscriber monetization and global scale. The bear case is margin pressure, legal and regulatory exposure, integration risk and a valuation that must be judged against high expectations. Keep the meme; do the diligence.

RE-READ THE FILE ↑

SYSTEM STATUS

COMPILING.

The confidence firmware is arranging itself into comic panels.